HAS-BLED Score Calculator

HAS-BLED Score Calculator for Cardiology. Scores are commonly grouped as low (0), intermediate (1-2), and high (3 or more). In the original Euro Heart Survey cohort, annual major bleeding rose stepwise from roughly 1% at low scores to about 12.5% at a score of 5, and validation cohorts show a similar gradient (approximately 1-3.4% at scores 0-2 rising to 8-13% at scores of 4-5). A score of 3 or greater marks a patient warranting closer follow-up and aggressive modification of reversible risk factors, not automatic exclusion from anticoagulation. Because bleeding and stroke risk factors overlap heavily (age, hypertension, prior stroke), high-HAS-BLED patients frequently gain the greatest absolute benefit from stroke prevention.

How this calculator works

HAS-BLED is a 9-point additive risk score that estimates the annual risk of major bleeding in patients with atrial fibrillation who are candidates for, or already receiving, oral anticoagulation. One point each is assigned for uncontrolled hypertension (systolic >160 mmHg), abnormal renal function, abnormal liver function, prior stroke, prior major bleeding or bleeding predisposition, labile INR (low time in therapeutic range on a vitamin K antagonist), age over 65 years, antiplatelet/NSAID use, and hazardous alcohol use. The renal/liver and drug/alcohol letters each carry two possible points, so the total ranges from 0 to 9. In the derivation cohort the score achieved a C-statistic of about 0.72 for one-year major bleeding.

When to use this calculator

Use HAS-BLED when deciding on and managing anticoagulation for non-valvular atrial fibrillation, typically alongside CHA2DS2-VASc for stroke risk. Its intended purpose in current ESC and ACC/AHA/ACCP/HRS guidance is not to withhold anticoagulation but to flag and correct modifiable bleeding risk factors (uncontrolled BP, labile INR, concomitant antiplatelet/NSAID use, alcohol excess) and to schedule earlier review. Do not use it as a standalone tool to deny anticoagulation to an otherwise stroke-eligible patient, and it was not derived for VTE, mechanical valves, or acute coronary syndrome antithrombotic decisions.

Inputs used

  • Blood pressure
  • Renal/liver disease
  • Stroke history
  • Bleeding history
  • INR control
  • Age
  • Drugs/alcohol

Clinical interpretation

Scores are commonly grouped as low (0), intermediate (1-2), and high (3 or more). In the original Euro Heart Survey cohort, annual major bleeding rose stepwise from roughly 1% at low scores to about 12.5% at a score of 5, and validation cohorts show a similar gradient (approximately 1-3.4% at scores 0-2 rising to 8-13% at scores of 4-5). A score of 3 or greater marks a patient warranting closer follow-up and aggressive modification of reversible risk factors, not automatic exclusion from anticoagulation. Because bleeding and stroke risk factors overlap heavily (age, hypertension, prior stroke), high-HAS-BLED patients frequently gain the greatest absolute benefit from stroke prevention.

Worked example

Consider a 78-year-old man with AF on warfarin who has hypertension controlled at 150/85, an eGFR of 40 mL/min, a time in therapeutic range of 55%, and daily low-dose aspirin for coronary disease. He scores: age over 65 (1) + abnormal renal function (1) + labile INR (1) + antiplatelet drug (1) = 4. A score of 4 sits in the high-risk band (roughly 8.7 major bleeds per 100 patient-years in validation data). The actionable read is not to stop anticoagulation but to address the modifiable drivers: reassess the need for aspirin, improve INR control or switch to a DOAC, and review renal dosing.

Limitations and safety notes

Discrimination is only modest, with C-statistics around 0.65-0.72 and as low as 0.50-0.67 in the fully anticoagulated SPORTIF validation cohort, so it separates groups better than it predicts individuals. The labile-INR item is undefined for patients on DOACs, limiting applicability in the modern anticoagulation era, and renal/liver "abnormality" thresholds are loosely specified. It was derived and validated in predominantly White European AF populations and can misclassify risk at the extremes; it should never be the sole reason to withhold guideline-indicated anticoagulation.

Frequently asked questions

Does a high HAS-BLED score mean I should stop anticoagulation?

No. A high score (3 or more) is a prompt to correct modifiable bleeding risks and follow the patient more closely, not to withhold anticoagulation. Stroke risk usually rises in parallel, so most high-HAS-BLED patients still benefit from anticoagulation.

How does HAS-BLED relate to CHA2DS2-VASc?

They are complementary. CHA2DS2-VASc estimates stroke risk and drives the decision to anticoagulate; HAS-BLED estimates bleeding risk and guides risk-factor modification and monitoring intensity. They share several factors (age, hypertension, prior stroke).

Can I use HAS-BLED for patients on a DOAC?

The score can still flag modifiable risks, but the labile-INR component is INR-based and does not apply to DOACs, so that point is typically scored zero. Interpret the total with this caveat in the DOAC era.

What blood pressure counts as hypertension for the score?

The hypertension point specifically refers to uncontrolled systolic blood pressure above 160 mmHg, not merely a diagnosis of treated hypertension.

Is a score of 3 an absolute cutoff for high risk?

It is the conventional threshold for the high-risk band and for intensified follow-up, but bleeding risk rises continuously with each point. Use the score as a graded signal rather than a hard binary gate.

References

  • Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-100. PMID: 20299623.
  • Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2010;57(2):173-80. PMID: 21111555.
  • Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. American College of Cardiology/American Heart Association. 2024.
  • Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Society of Cardiology. 2024.

Editorial review and citation methodology

Reviewed by the Quick Medical Calculator Editorial Team. Last reviewed: March 7, 2026. The review checks calculator inputs, intended population, interpretation, limitations, and source alignment.

  • Prefer original validation studies for scoring systems and prediction tools.
  • Use current specialty society guidance, transplant allocation policy, public health guidance, or regulator resources when they govern clinical use.
  • Include limitations and safety notes when a calculator is population-specific, context-dependent, or unsuitable as a standalone decision tool.

Related reviewed calculators